Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Evaluation of anti-tumour activities of the novel small molecule PRIMA-1met in Waldenstrom Macroglobulinemia
EF 2013-14
Résumé
Waldenstrom macroglobulinemia (WM) is a cancer of terminally differentiated B-cells, ie. plasma cells, which play major roles in white blood cells immunity. The faith of WM patients is very heterogeneous but the 5 year survival rate is reported to be 50%.1 Current medications used for WM patients are not highly effective and the chances of reoccurrence are great. Therefore, finding an alternative treatment is a priority for people working in this area. PRIMA-1met is a drug which has shown promising results in phase I/II clinical trials in patients with hematological and prostate cancer.2 This drug is a small molecule agent that restores the wild type conformation of mutant P53. P53, a tumor suppressor, in turn plays a major role in causing cell death in cancer cells. Therefore, targeting P53 with small molecules such as PRIMA-1met can be an attractive therapeutic strategy. My research will focus on laying the preclinical ground work needed for further evaluation of PRIMA-1met as a novel therapeutic approach for the treatment of WM patients. I will investigate the cell viability and the changes in the internal protein network of the WM cells after administrating PRIMA-1met in order to examine its level of cytotoxicity and effectivity in killing WM cancer cells and elucidate the cellular pathways this drug affects.
References:
1. Dhodapkar MV, Hoering A, Gertz MA et al.(2009). Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.Blood 113(4):793-6.
2. Lehmann S., Bykov V.J., Ali D. et al. (2012). Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol.30(29):3633-9.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
311749
Name
Sobhani Mona
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluation of anti-tumour activities of the novel small molecule PRIMA-1met in Waldenstrom Macroglobulinemia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Cancer Drug; Apoptosis; Lymphoplasmacytic Lymphoma; P53; Prima-1met; Small Molecule Drugs; Waldenstrom Macroglobulinemia
Abstract
Waldenstrom macroglobulinemia (WM) is a cancer of terminally differentiated B-cells, ie. plasma cells, which play major roles in white blood cells immunity. The faith of WM patients is very heterogeneous but the 5 year survival rate is reported to be 50%.1 Current medications used for WM patients are not highly effective and the chances of reoccurrence are great. Therefore, finding an alternative treatment is a priority for people working in this area. PRIMA-1met is a drug which has shown promising results in phase I/II clinical trials in patients with hematological and prostate cancer.2 This drug is a small molecule agent that restores the wild type conformation of mutant P53. P53, a tumor suppressor, in turn plays a major role in causing cell death in cancer cells. Therefore, targeting P53 with small molecules such as PRIMA-1met can be an attractive therapeutic strategy. My research will focus on laying the preclinical ground work needed for further evaluation of PRIMA-1met as a novel therapeutic approach for the treatment of WM patients. I will investigate the cell viability and the changes in the internal protein network of the WM cells after administrating PRIMA-1met in order to examine its level of cytotoxicity and effectivity in killing WM cancer cells and elucidate the cellular pathways this drug affects.
References:
1. Dhodapkar MV, Hoering A, Gertz MA et al.(2009). Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.Blood 113(4):793-6.
2. Lehmann S., Bykov V.J., Ali D. et al. (2012). Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol.30(29):3633-9.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sobhani, Mona
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~